The lab-developed blood test measures the quantity and quality of antibodies present in the body. Credit: Hush Naidoo Jade Photography / Unsplash.

Biotech innovation company Aditxt has submitted two applications to the US Food and Drug Administration (FDA) seeking emergency use authorisation (EUA) for its AditxtScore for COVID-19 tests.

The new lab-developed blood test is designed to measure the quantity and quality of Covid-19 antibodies present in the body, including those for its common variants, such as Omicron.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It provides a comprehensive profile of the protective immunity against Covid-19 in the body.

The company said that its immune profile technology AditxtScore for COVID-19 also seeks to explore the difference in response to Covid-19 common variants.

It submitted the applications to the FDA for its AditxtScore for COVID-19 tests, which are designed to measure the level of antibodies that can attack different virus targets, including the spike and nucleocapsid proteins, and reveal levels of antibodies that neutralise Covid-19.

Aditxt co-founder and CEO Amro Albanna said: “Understanding the levels of antibodies to Covid-19 and the effectiveness of these antibodies to neutralise the virus is key to a successful national and global response to the pandemic.

“AditxtScore for COVID-19 and its decoding of the immune response to SARS-CoV-2 plays a vital role in providing such critically needed information and helping us return to normality.”

During the FDA review, the availability of AditxtScore for COVID-19 will continue.

With the help of AditxtScore for COVID-19, individuals will be able to get a better understanding of their immunity status.

Last year, the company launched the AditxtScore Immune Monitoring Center in Richmond, Virginia.

The facility was certified by the Clinical Laboratory Improvement Amendments (CLIA).